Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
|
|
10.
|
|
|
11.
|
|
|
12.
|
|
|
13.
|
Erratum: Clinical responses to ERK inhibition in [electronic resource] by
- Kirouac, Daniel C
- Schaefer, Gabriele
- Chan, Jocelyn
- Merchant, Mark
- Orr, Christine
- Huang, Shih-Min A
- Moffat, John
- Liu, Lichuan
- Gadkar, Kapil
- Ramanujan, Saroja
Publication details: NPJ systems biology and applications 2017
In:
NPJ systems biology and applications vol. 3
Availability: No items available.
|
|
14.
|
Clinical responses to ERK inhibition in [electronic resource] by
- Kirouac, Daniel C
- Schaefer, Gabriele
- Chan, Jocelyn
- Merchant, Mark
- Orr, Christine
- Huang, Shih-Min A
- Moffat, John
- Liu, Lichuan
- Gadkar, Kapil
- Ramanujan, Saroja
Publication details: NPJ systems biology and applications 2017
In:
NPJ systems biology and applications vol. 3
Availability: No items available.
|
|
15.
|
|
|
16.
|
Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. [electronic resource] by
- Kirouac, Daniel C
- Du, Jin Y
- Lahdenranta, Johanna
- Overland, Ryan
- Yarar, Defne
- Paragas, Violette
- Pace, Emily
- McDonagh, Charlotte F
- Nielsen, Ulrik B
- Onsum, Matthew D
Producer: 20140414
In:
Science signaling vol. 6
Availability: No items available.
|
|
17.
|
A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. [electronic resource] by
- Wagle, Marie-Claire
- Kirouac, Daniel
- Klijn, Christiaan
- Liu, Bonnie
- Mahajan, Shilpi
- Junttila, Melissa
- Moffat, John
- Merchant, Mark
- Huw, Ling
- Wongchenko, Matthew
- Okrah, Kwame
- Srinivasan, Shrividhya
- Mounir, Zineb
- Sumiyoshi, Teiko
- Haverty, Peter M
- Yauch, Robert L
- Yan, Yibing
- Kabbarah, Omar
- Hampton, Garret
- Amler, Lukas
- Ramanujan, Saroja
- Lackner, Mark R
- Huang, Shih-Min A
Publication details: NPJ precision oncology 2018
In:
NPJ precision oncology vol. 2
Availability: No items available.
|
|
18.
|
Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors. [electronic resource] by
- Merchant, Mark
- Moffat, John
- Schaefer, Gabriele
- Chan, Jocelyn
- Wang, Xi
- Orr, Christine
- Cheng, Jason
- Hunsaker, Thomas
- Shao, Lily
- Wang, Stephanie J
- Wagle, Marie-Claire
- Lin, Eva
- Haverty, Peter M
- Shahidi-Latham, Sheerin
- Ngu, Hai
- Solon, Margaret
- Eastham-Anderson, Jeffrey
- Koeppen, Hartmut
- Huang, Shih-Min A
- Schwarz, Jacob
- Belvin, Marcia
- Kirouac, Daniel
- Junttila, Melissa R
Publication details: PloS one 2018
In:
PloS one vol. 13
Availability: No items available.
|
|
19.
|
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors. [electronic resource] by
- Merchant, Mark
- Moffat, John
- Schaefer, Gabriele
- Chan, Jocelyn
- Wang, Xi
- Orr, Christine
- Cheng, Jason
- Hunsaker, Thomas
- Shao, Lily
- Wang, Stephanie J
- Wagle, Marie-Claire
- Lin, Eva
- Haverty, Peter M
- Shahidi-Latham, Sheerin
- Ngu, Hai
- Solon, Margaret
- Eastham-Anderson, Jeffrey
- Koeppen, Hartmut
- Huang, Shih-Min A
- Schwarz, Jacob
- Belvin, Marcia
- Kirouac, Daniel
- Junttila, Melissa R
Producer: 20171031
In:
PloS one vol. 12
Availability: No items available.
|